Journal of Chromatography B

Journal of Chromatography B - ISSN 1570-0232
Source Normalized Impact per Paper (SNIP): 1.027 Source Normalized Impact per Paper (SNIP):
SNIP measures contextual citation impact by weighting citations based on the total number of citations in a subject field.
SCImago Journal Rank (SJR): 0.729 SCImago Journal Rank (SJR):
SJR is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and a qualitative measure of the journal’s impact.
Impact Factor: 3.205 (2020) Impact Factor:
The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.
© 2017 Journal Citation Reports ® (Clarivate Analytics, 2017)
5 Year Impact Factor: 3.068 (2020) Five-Year Impact Factor:
To calculate the five year Impact Factor, citations are counted in 2016 to the previous five years and divided by the source items published in the previous five years.
© 2017 Journal Citation Reports ® (Clarivate Analytics, 2017)
Volumes: Volume 26
Issues: 26 issues
ISSN: 15700232
Editor-in-Chief: Hage

Institutional Subscription

Sales tax will be calculated at check-out Price includes VAT/GST
This journal does not feature personal pricing and is not available for personal subscription.

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.


The Journal of Chromatography B publishes papers on developments in separation science relevant to biology and biomedical research including both fundamental advances and applications. Analytical techniques which may be considered include the various facets of chromatography, electrophoresis and related methods, affinity and immunoaffinity-based methodologies, hyphenated and other multi-dimensional techniques, and microanalytical approaches. The journal also considers articles reporting developments in sample preparation, detection techniques including mass spectrometry, and data handling and analysis.

Developments related to preparative separations for the isolation and purification of components of biological systems may be published, including chromatographic and electrophoretic methods, affinity separations, field flow fractionation and other preparative approaches.

Applications to the analysis of biological systems and samples will be considered when the analytical science contains a significant element of novelty, e.g. a new approach to the separation of a compound, novel combination of analytical techniques, or significantly improved analytical performance. Areas to be considered include:

  • The qualitative and quantitative analysis of biopolymers including proteins, monoclonal antibodies, peptides and their post-translational modifications as well as nucleic acids and glycans
  • The comparative analysis of biological systems using proteomics, genomics, metabolomics, lipidomics and other "omics" approaches
  • Clinical analysis, metabolism, therapeutic drug monitoring, toxicological analysis, doping analysis, veterinary applications, analysis of environmental contaminants in biological systems
  • The screening and profiling of body fluids, tissues, cells, biological matrices and systems, analysis of endogenous compounds, biomarkers
  • Identification of new bioactive compounds

Applications which utilize published or commercial analytical or preparative protocols with little or no modification or where the results of the application rather than the analytical methodology comprise the major element of novelty of the manuscript should be directed to more specialized journals. Modifications to a previously published method may be considered for a short communication in cases where the improvement in performance is significant. Reports of analytical methods for compounds in early pharmaceutical development often lack general interest and will not be published unless the authors can demonstrate the broader significance of the methodology involved. Quality control analyses of bulk drugs, natural products or pharmaceutical formulations of small molecules are not within scope.